Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : CAVALRY'S SHORT BUSTERS - MAGIC EIGHTBALLS PICKS -- Ignore unavailable to you. Want to Upgrade?

To: Janice Shell who wrote (1381)	10/26/1998 1:29:00 PM
From: Ellen	Read Replies (1) \| Respond to of 1637

Well, as usual, you ignore questions posed to you. So what else is new? And your opinion means so much, ya know? After all, it's substantiated, right? Like the rest of your opinions? Oh, and your "facts" too? Um, yeah...

To: Janice Shell who wrote (1381)	10/26/1998 4:15:00 PM
From: Cavalry	Read Replies (1) \| Respond to of 1637

this is not good for you and poof, what the heck is a as you called it scam stock like cygs putting out legitimate news like this, did you blow cygs too?????? please tell me southwest foundation for biomedical research is two guys working from their house not a legitimate research facility. please tell me you got one right. CYGS Initiates Antisense Animal Studies Business Wire - October 23, 1998 19:15 HOUSTON--(BUSINESS WIRE)--Oct. 23, 1998--Cryogenic Solutions Inc. (OTC BB:CYGS) announced it has recently entered into an agreement with the Southwest Foundation for Biomedical Research to undertake animal testing of its proprietary ssDNA expression vector. The tests will be conducted by Dr. Jason T. Kimata and supervised by Dr. Jean L. Patterson, chairman of the Department of Virology and Immunology. The animal studies are intended to demonstrate the ability of the ssDNA expression vector to synthesize pharmacologically significant titers of sequence specific, antisense competent oligodeoxyribonucleotides intracellularly in an animal model. "We expect to show in a primate that we have overcome the oligo delivery barrier and with controllable expression of ssDNA," said company president, Laurence Mealey. Tests will commence in late November. In addition the company announced plans to begin shipping ssDNA expression vector kits in late November. The kits will be provided to researchers for experimental purposes only and are governed by Materials Transfer Agreements between CYGS and the research facilities. A number of premiere universities and hospitals have requested such agreements to date. The agreements cover commercialization of all discoveries and developments resulting from the use of the company's technology. CYGS is also entertaining overtures from a number of major pharmaceutical companies. CONTACT: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399